“HR Positive/ HER2 Negative Breast Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the HR Positive/ HER2 Negative Breast Cancer Market.
The HR Positive/ HER2 Negative Breast Cancer Pipeline report embraces in-depth commercial, regulatory, and HR Positive/ HER2 Negative Breast Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging HR Positive/ HER2 Negative Breast Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
HR Positive/ HER2 Negative Breast Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for HR Positive/ HER2 Negative Breast Cancer treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different HR Positive/ HER2 Negative Breast Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major HR Positive/ HER2 Negative Breast Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the HR Positive/ HER2 Negative Breast Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the HR Positive/ HER2 Negative Breast Cancer therapeutic market.
HR Positive/ HER2 Negative Breast Cancer Therapeutics Landscape
The present goal of therapy for early HR+/HER2- breast cancer (BC) is to optimize disease-free survival (DFS) and overall survival (OS) rates with the currently available therapies while avoiding any relevant long-term sequalae. Local therapies have evolved toward less aggressive techniques (i.e. breast-preserving surgery, sentinel lymph node biopsy, and intraoperative radiotherapy), which significantly reduce the long-term sequalae observed with more radical treatments. Endocrine therapy (ET) is still the cornerstone of adjuvant treatment because it significantly reduces BC relapse and mortality. Adjuvant chemotherapy is recommended only for a particular subset of patients with a high risk of recurrence with ET alone, identified through genomic assays, age, and/or disease stage. Bisphosphonates reduce the risk of bone metastasis and produce a slight although statistically significant improvement in survival in postmenopausal women. The CDK 4/6 inhibitor Abemaciclib has been recently approved by the US FDA for patients at high risk of relapse.
There are approx. 50+ key companies are developing therapies for HR Positive/ HER2 Negative Breast Cancer. Currently, AstraZeneca is leading the therapeutics market with its HR Positive/ HER2 Negative Breast Cancer drug candidates in the most advanced stage of clinical development.
HR Positive/ HER2 Negative Breast Cancer Companies Actively Working in the Therapeutic Market Include:
-
Regor Therapeutics
-
Seagen Inc.
-
CytomX Therapeutics
-
Taizhou EOC Pharma
-
Chia Tai Tianqing Pharmaceutical Group
-
AstraZeneca
-
Daiichi Sankyo, Inc.
-
Tyme, Inc.
-
Seagen Inc.
-
Context Therapeutics
-
Eisai Inc.
-
Shanghai Hengrui Pharmaceutical Co., Ltd.
-
Jiangsu Simcere Pharmaceutical Co.,
-
Kind Pharmaceuticals
-
Merus N.V.
-
Atossa Therapeutics
-
Roche
And Many Others
Emerging and Marketed HR Positive/ HER2 Negative Breast Cancer Drugs Covered in the Report Include:
-
Camizestrant: AstraZeneca
-
Dato-DXd: Daiichi Sankyo, Inc.
-
CX-2009: CytomX Therapeutics
-
RGT-419B: Regor Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and HR Positive/ HER2 Negative Breast Cancer Companies Working in the Market @
https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight
Analysis of Emerging HR Positive/ HER2 Negative Breast Cancer Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Learn How the HR Positive/ HER2 Negative Breast Cancer Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. HR Positive/ HER2 Negative Breast Cancer Treatment Patterns
4. HR Positive/ HER2 Negative Breast Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. HR Positive/ HER2 Negative Breast Cancer Late Stage Products (Phase-III)
7. HR Positive/ HER2 Negative Breast Cancer Mid-Stage Products (Phase-II)
8. HR Positive/ HER2 Negative Breast Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. HR Positive/ HER2 Negative Breast Cancer Discontinued Products
13. HR Positive/ HER2 Negative Breast Cancer Product Profiles
14. Major HR Positive/ HER2 Negative Breast Cancer Companies in the Market
15. Key Products in the HR Positive/ HER2 Negative Breast Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. HR Positive/ HER2 Negative Breast Cancer Unmet Needs
18. HR Positive/ HER2 Negative Breast Cancer Future Perspectives
19. HR Positive/ HER2 Negative Breast Cancer Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Empowering Cancer Care: DelveInsight’s oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details: Oncology Market Research
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices